American College of Cardiology

Journalists: please note that all presentations are embargoed until the time of their actual presentation at the Late-Breaking Clinical Trial (LBCT) sessions. The date and time of each official presentation at an LBCT session is provided at the end of each trial topic description.

Highlights from:

SUNDAY | MONDAY | TUESDAY | WEDNESDAY

SUNDAY, MARCH 7, 2004
Results from Sunday

8:00 - 8:45 a.m.
Late Breaking Clinical Trials in Interventional Cardiology: Coronary and Peripheral Revascularization

• A Randomized Comparison of Sirolimus-Eluting Stent and a Standard Stent in the Prevention of Restenosis in Small Coronary Arteries: The SES-SMART Trial— Diego Ardissino, MD, Università Degli Studi di Parma, Parma, Italy (Session #22, March 7, 9:30 a.m.)
• Direct Stenting Using the Sirolimus-Eluting Bx VELOCITY™ Stent: Procedural, Clinical and Angiographic Outcomes Compared to a Predilation Strategy—Jeffrey W. Moses, MD, Lenox Hill Hospital, New York (Session #22, March 7, 9:45 a.m.)
• One-Year Coronary Bypass Graft Patency: A Randomized Comparison Between Off-Pump and On-Pump Surgery—Angiographic Results of the PRAGUE-4 Trial—Petr Widimsky, MD, CardioCenter Vinohrady, Czech Republic (Session #22, March 7, 10:00 a.m.)
• Final Composite Endpoint Results for the ARCHcR Study 1-Year Results: ACCULINK™ for Revascularization of Carotids in High Risk Patients—William A. Gray, MD, Seattle Heart, Swedish Medical Center, Seattle, WA (Session #22, March 7, 10:15 a.m.)

Moderator: George A. Mensah, MD, FACP, FACC, FESC, Chief, Cardiovascular Health Branch, Centers for Disease Control and Prevention, Atlanta, GA
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

9:30 - 10:30 a.m.
Break for Session #22: Late Breaking Clinical Trials in Interventional Cardiology: Coronary and Peripheral Revascularization—A detailed look at the studies presented at the 8:00 a.m. Press Conference on Late Breaking Clinical Trials in Interventional Cardiology: Coronary and Peripheral Revascularization.

11:00 - 11:45 a.m.
Women and Heart Disease—Women make strides in cardiology care and training. Studies presented highlight advances in the diagnosis and treatment of women with heart disease, as well as in the number of women training to become cardiologists.

• Women in Cardiology—Bridging the Gender Gap—Linda Dawn Gillam, MD, Hartford Hospital, Hartford, CT (Session #1059, March 8, 12:00 p.m.)
• In Women with Symptoms of Ischemic Heart Disease, Global and Regional Myocardial Perfusion Status by MRI Better Assigns Risk: Results from the NHLBI-Sponsored Women's Ischemia Syndrome Evaluation (WISE)—Mark Doyle, MD, Allegheny General Hospital, Pittsburgh, PA (Session #801-1, March 8, 9:15 a.m.)
• Women with Diabetes Mellitus Have the Greatest Reduction in MI Mortality Over the Past Decade: Evaluation of 1,428,596 Patients Enrolled in the National Registry of Myocardial Infarction (NRMI) 2, 3 & 4 from 1994-2002—Darren K. McGuire, MD, University of Texas Southwestern Medical Center, Dallas, TX (Session 827-3, March 8, 4:30 p.m.)
• The Duke Treadmill Score and Cardiac Mortality in Asymptomatic Women: The St. James Women Take Heart Project—Martha Gulati, MD, Rush University Medical Center, Chicago, IL (Session 876-1, March 10, 8:30 a.m.)

Moderator: Marian C. Limacher, MD, University of Florida, Division of Cardiovascular Medicine, Gainesville, FL
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

12:00 - 12:15 p.m.
Cardiac Surgery—Innovation marks new approaches to repairing the heart. Studies highlight innovative advances in the treatment of coronary artery disease, the repair of leaky heart valves, and the use of devices to assist the failing heart—while also examining key questions about cost and outcomes.

• Financial Impact of Drug-Eluting Stents: The U.S. Academic Experience—David Marks, MD, Medical College of Wisconsin, Milwaukee, WI (Session 1040-73, March 7, 1:00 p.m.)
• Percutaneous Edge-to-Edge Repair for Mitral Regurgitation Guided by Transesophageal and Transthoracic Echocardiography—William Stewart, MD, Cleveland Clinic Foundation, Cleveland, Ohio (Session #1116-25, March 9, 12:00 p.m.)
• Cardiac Recovery During Left Ventricular Assist Device (LVAD) Support: Results from the LVAD Working Group—Simon Maybaum, MD, Columbia University, New York, NY (Session 856-2, March 9, 4:15 p.m.)

Moderator: Lawrence H. Cohn, MD, Brigham & Women's Hospital, Boston, MA
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

1:00 - 1:30 p.m.
Unveiling of the Red Dresses. Mosaic Fountain, Lobby A of the Morial Convention Center.

• Carl J. Pepine, MD, president of the American College of Cardiology (ACC)
• Patrick Holmes, vice president of cardiology, Pfizer
• Augustus O. Grant, president, American Heart Association (AHA)
• Barbara Alving, MD, acting director, National Heart, Lung, and Blood Institute (NHLBI)

2:00 - 3:00 p.m.
Late Breaking Clinical Trials and Trial Updates: Novel Therapies for Acute Myocardial Infarction

• Primary Angioplasty in Acute Myocardial Infarction with Distal Protection of the Microcirculation: Principal Results from the Prospective, Randomized EMERALD Trial—Bruce Brodie, MD, Moses Cone Heart and Vascular Center, LeBauer Cardiovascular Research Foundation, Greensboro, NC (Session #25, March 7, 4:00 p.m.)
• Acute Myocardial Infarction with Hyperoxemic Therapy (AMIHOT): A Prospective, Randomized Multicenter Trial—Jack Martin, MD (Session #25, March 7, 4:15 p.m.)
• Reduction of Infarct Size and Improved Left Ventricular Function with Intravenous Caldaret (MCC-135) and Primary Percutaneous Coronary Intervention for ST Elevation Myocardial Infarction—Dan Tzivoni, MD, Shaare Zedek Medical Center, Jerusalem, Israel (Session #25, March 7, 4:45 p.m.)
• Combined Angioplasty and Pharmacological Intervention vs. Thrombolytics Alone in Acute Myocardial Infarction (CAPITAL AMI)—Michel R. LeMay, MD, University of Ottawa, Canada (Session #25, March 7, 5:00 p.m.)
• Percutaneous Transvenous Transplantation of Autologous Myobiasts in the Treatment of Postinfarction Heart Failure: The POZNAN Trial—Tomasz Siminiak, MD, Professor of Cardiology, University School of Medical Sciences, Department of Cardiology, District Hospital, Poznan, Poland (Session #25, March 7, 5:15 p.m.)

Moderator: David O. Williams, MD, Rhode Island Hospital, Providence, RI
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

3:15 - 3:45 p.m.
ACC / GE Healthcare Cardiovascular Career Development Award
Announcement of an exciting new initiative, the ACCF/GE Healthcare Cardiovascular Career Development Award, to improve the practice of cardiology by investing in its future practitioners.

• Laura King, general manager, cardiology and surgery, GE Healthcare
• Carl J. Pepine, MD, president, American College of Cardiology
• Bob Davis, general manager, americas cardiology sales and marketing, GE Healthcare
• Pam Douglas, MD, 1992 recipient of the ACC/Merck Fellowship International Exchange

4:00 - 5:30 p.m.
Break for Session #25: Late Breaking Clinical Trials and Trial Updates: Novel Therapies for Acute Myocardial Infarction
A more detailed look at the studies presented at the 2:00 p.m. Press Conference on Late Breaking Clinical Trials and Trial Updates: Novel Therapies for Acute Myocardial Infarction

MONDAY, MARCH 8, 2004
Results from Monday

8:00 - 10:00 a.m.
Presidential Plenary Session/Simon Dack Lecture
Predicting the Management of Cardiovascular Disease in 2010: The Potentials of Gene, Molecular and Cell-Based Therapies, Victor J. Dzau, Boston, MA

9:45 - 11:00 a.m.
Late Breaking Clinical Trials I

• Sudden Cardiac Death-Heart Failure Trial—Gust H. Bardy, MD, University of Washington Medical Center, Seattle, WA (Session #402, March 8, 10:30 a.m.)
• Randomized Trial of Prophylactic Implantable Defibrillator Therapy vs. Optimal Medical Treatment Early After Myocardial Infarction: The Defibrillator in Acute Myocardial Infarction Trail—Stefan H. Hohnloser, MD, J.W. Goethe-University College, Frankfurt, Germany (Session #402, March 8, 10:45 a.m.)
• The PAVE Trial: The First Prospective, Randomized Study Evaluating BV Pacing After Ablate and Pace Therapy—Rahul Doshi, MD, Sunrise Hospital and Medical Center, Las Vegas, NV (Session #402, March 8, 10:00 a.m.)
• Pravastatin or Antorvastatin Evaluation and Infection Therapy: Thrombolysis in Myocardial Infarction 22 (PROVE IT-TIMI 22)—Statin Comparison—Christopher P. Cannon, MD, Brigham & Women's Hospital, Boston, MA (Session #402, March 8, 9:45 a.m.)
• Comparison of Clinical Outcomes in Managed Care Patients with Coronary Heart Disease Treated in Aggressive Lipid Lowering Programs Using Atorvastatin vs. Usual care: The ALLIANCE Study—Donald B. Hunninghake, MD, University of Minnesota, Minneapolis, MN (Session #402, March 8, 10:15 a.m.)

Moderator: George A. Mensah, MD, FACP, FACC, FESC, Chief, Cardiovascular Health Branch, Centers for Disease Control and Prevention, Atlanta, GA.
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

12:15 - 12:45 p.m.
Stents/PCI—Studies explore the effect of medication on stenting process
The treatment of coronary artery disease increasingly combines catheter-based procedures to open narrowed coronary arteries and powerful medications to prevent new obstructions. Studies being presented provide new insight into this dual approach.

• REDOX Trial—Reduced Sirolimus Doses on the Bx/VELOCITYTM Stent: Four Month Results—Alexandre Abizaid, MD, Institute Dante Pazzanese of Cardiology, Sao Paulo, Brazil (Session #843-1, March 9, 2:00 p.m.)
• Long Term Results of ISAR-REACT—A Randomized Trial Evaluating Abciximab in Patients with Elective PCI after Pretreatment with a High Loading Dose of Clopidogrel—Helmut Schuhlen, MD, Deutsches Herzzentrum Munchen, Munich, Germany (Session #1001-8, March 7, 12:00)

Moderator: William W. O'Neill, MD, William Beaumont Hospital, Royal Oak, MI
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

1:00 p.m.-1:45 p.m.
Ischemic Heart Disease—Research offers clues to causes, treatments for heart disease
Studies shed light on novel catheter-based treatments for patients with severe heart disease, new genetic markers for predicting the risk of renarrowing after stenting, and the link between sudden cardiac illness and inflammation elsewhere in the body.

• One-Year Follow-Up of Transendocardial Injection of Autologous Bone Marrow Mononuclear Cells for Ischemic Cardiomyopathy—Emerson C. Perin, MD, Texas Heart Institute, Houston, TX (Session #864-2, March 10, 8:45 a.m.)
• Transendocardial Autologous Bone Marrow Cell Transplantation in Patients with Advanced Ischemic Heart Disease: Final Results from a Multi-Center Feasibility Study—Shmuel Fuchs, MD, Rabin Medical Center, Petch-Tikva, Israel (Session #864-3, March 10, 9:00 a.m.)
• The IL-6-174G/C Polymorphism is a Powerful Predictor for Restenosis After Coronary Stent Implantation—Tonya Kottman, MD, Heart Center, Department of Cardiology, Bad Deynhausen, Germany (Session 803-3, March 8, 9:45 a.m.)
• Urinary Tract Infection in Patients with Acute Coronary Syndrome: A Potential Systemic Inflammatory Connection—John B. Sims, MD, University of Texas Southwestern Medical Center, Dallas, TX (Session #1001-3, March 7, 12:00 p.m.)

Moderator: Thomas J. Ryan, MD, Boston University Medical Center, Boston, MA
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

2:00 p.m.-2:45 p.m.
Public Health—Patient’s state of mind, activity level important in overcoming heart disease
Successful treatment of heart disease requires more than clinical excellence. Studies highlight the importance of patient motivation and the possible consequences of a sedentary lifestyle.

• Eliminating Angina Enhances Patients' Return to Work after Percutaneous Coronary Intervention—Avinash Khanna, MD, University of Missouri-Kansas City, Kansas City, MO (Session # 1138-45, March 9, 1:00 p.m.)
• Physical Inactivity and Increased Thrombotic Risk: The Framingham Heart Study—Geoffrey H. Tofler, MD, Royal North Shore Hospital, Sydney, Australia (Session 876-4, March 10, 9:15 a.m.)
• Higher Coronary Calcification Scores Improve Adherence in Cardiac Risk Factor-Modifying Behavior—Matthew J. Budoff, MD, Harbor-UCLA Medical Center, Torrance, CA (Session #845-1, March 9, 2:00 p.m.)

Moderator: Martha Radford, MD, Yale New Haven Health System, New Haven, CT
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

Press Conferences
TUESDAY, MARCH 9, 2004

7:30 a.m.-8:00 a.m.
Electrophysiology Studies—New ideas in arrhythmia therapy
Studies take a fresh look at identifying which patients are at highest risk for serious cardiac arrhythmias, the potential for a common heart failure drug to reduce the likelihood of developing arrhythmias, and the health consequences of limiting reimbursement for new therapies.

• Potential Impact of MADIT II and CMS Criteria on Care of Patients Diagnosed with Myocardial Infarction— Richard F. Otten, MD, University of Michigan, Ann Arbor, MI (Session #846-3, March 9, 2:30 p.m.)
• Angiotensin-Converting Enzyme Inhibitors Reduce the Incidence of Implantable Cardioverter Defibrillator Therapy in Idiopathic Dilated Cardiomyopothy with Congestive Heart Failure—Fei Lu, MD, University of Minnesota, Minneapolis, MN (Session #817-4, March 8, 2:45 p.m.)

Moderator: Douglas P. Zipes, MD, Indiana University School of Medicine, Indianapolis, IN
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

8:15 a.m.-10:00 a.m.
Break for Session #409: Late Breaking Clinical Trials II
A detailed look at the studies presented at the upcoming (10:30 a.m.) Press Conference on Late Breaking Clinical Trials

10:30 a.m.-11:30 a.m.
Late Breaking Clinical Trials II

• Effects of Rimonabant in the Reduction of Major Cardiovascular Risk Factors. Results from the STRATUS-US Trial (Smoking Cessation in Smokers Motivated to Quit) and the RIO-LIPIDS Trial (Weight Reducing and Metabolic Effects in Overweight / Obese Patients with Dyslipidemia)—Robert M. Anthenelli, MD, University of Cincinnati College of Medicine, Cincinnati, Ohio; and Jean-Pierre Despres, Ph.D., Department of Human Nutrition at Laval University and Director of Research, Cardiology, Laval Hospital Research Center, Quebec, Canada, (Session #409-1, March 9, 8:15 a.m.)
• Long Term Follow Up of Safety and Feasibility of Autologous Skeletal Myoblast Transplantation in Patients Undergoing Coronary Artery Bypass Graft Surgery—Nabil Dib, MD, Arizona Heart Institute, Phoenix, AZ (Session #409-1, March 9, 8:30 a.m.)
• Final Results of the Warfarin and Antiplatelot Trial in Chronic Heart Failure (WATCH): A Randomized Comparison of Warfarin, Aspirin and Clopidogrel—Barry M. Massie, MD, San Francisco VAMC, University of California, San Francisco, CA (Session #409-1, March 9, 9:15 a.m.)
• Percutaneous Mitral Valve Repair Using the Edge-to-Edge Technique: Phase I U.S. Trial Results— Ted Feldman, MD, Evanston Northwestern Healthcare, Evanston Hospital, Evanston, IL (Session #409-1, March 9, 9:00 a.m.)
• The Superior Yield of the New Strategy of Enoxaparin, Revascularization and Glycoprotein Ilb/IIIa Inhibitors (SYNERGY) Trial: Primary Results—Robert M. Califf, MD, Duke Clinical Research Institute, Durham, NC (Session #409-1, March 9, 8:45 a.m.)
• Low Blood Pressure is Associated with Increased Mortality and Cardiovascular Morbidity (J-Shaped Curve) in Treated Hypertensive Patients with Coronary Artery Disease: The International Verapamil SR-Trandolapril Study (INVEST)—Franz H. Messerli, MD, Ochsner Clinic Foundation, New Orleans, LA (Session #409-1, March 9, 9:30 a.m.)
• Racial Differences in Benefits of Angiotensin-Converting Enzyme Inhibitors in Hypertension: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial Experiments—Curt D. Furberg, MD, Wake Forest University School of Medicine, Winston-Salem, NC (Session #409-1, March 9, 9:45 a.m.)

Moderator: Mitchell W. Krucoff, MD, Duke University Medical Center, Durham, NC
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

12:00 p.m.-12:45 p.m.
Acute Myocardial Infarction—Statins, ACE inhibitors play key role in heart attack survival
New research highlights the importance of statins, angiotensin-converting-enzyme (ACE) inhibitors, and blood thinners in improving short- and long-term survival of patients with heart attack and acute coronary syndromes.

• Use of Angiotensin-Converting Enzyme Inhibitors after Acute Myocardial Infarction is Associated with a Striking Reduction in 30-Day and One-Year Mortality: Insights from GUSTO V—Deepak Vivekananthan, MD, The Cleveland Clinic Foundation, Cleveland, Ohio (Session #833-1, March 9, 8:30 a.m.)
• Long-Term Effects of Statin Therapy in Patients with Acute ST-Elevation Myocardial Infarction and Moderate or Severe Left Ventricular Dysfunction: Reduction of Mortality but Not of Nonfatal Major Adverse Coronary and Cerebrovascular Events—Thomas Kleeman, MD, Herzzentrum Ludwigshafen, Ludwigshafen, Germany (Session 833-2, March 9, 8:45 a.m.)
• Statin Therapy and Mortality in Patients with Acute Myocardial Infarction Treated with Primary Angioplasty—Giuseppe De Luca, MD, Division of Cardiology, De Weezenlanden Hospital, Zwolle, The Netherlands (Session #833-3, March 9, 9:00 a.m.)
• Sex Disparities in the Treatment of Non-ST Segment Elevation Acute Coronary Syndrome—Andra Blomkalns, MD, University of Cincinnati, Department of Emergency Medicine, Cincinnati, Ohio (Session 864-4, March 10, 9:15 a.m.)
• Direct, Selective, Factor Xa Inhibition in Patients with Non-ST Elevation Acute Coronary Syndrome from the U.S., Canada, and Japan: Results of the XaNADU Trial—John H. Alexander, MD, and Robert A. Harrington, MD, Duke University Medical Center, Durham, NC (Session 861-1, March 9, 4:00 p.m.)

Moderator: William E. Boden, MD, Hartford Hospital, University of Connecticut School of Medicine, Hartford, CT
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

1:00 p.m.-1:45 p.m.
Metabolic Syndrome—Studies detail harmful effects of metabolic syndrome
Obesity and diabetes markedly increase the risk of cardiovascular disease, whether separately or as part of the “metabolic syndrome.” Studies presented provide new insight into the harmful relationship between blood glucose, body weight, blood lipids, high blood pressure, and inflammation.

• Comparative Effects of Statins on Atherogenic Dyslipidemia in Patients with the Metabolic Syndrome—Prakash Deedwania, MD, VACCHA/UCSF School of Medicine, Fresno, CA (Session #820-1, March 8, 2:00 p.m.)
• Obesity as an Independent Predictor of First Atrial Fibrillation in Adults Aged >65 Years—Kent E. Bailey, MD, Mayo Clinic, Rochester, MN (Session #865-5, March 10, 11:30 a.m.)
• Risk of Cardiovascular Disease in U.S. Persons with Metabolic Syndrome, Diabetes and Elevated C-Reactive Protein—Shaista Malik, MD, University of California-Irvine, Irvine, CA (Session #820-2, March 8, 2:15 p.m.)
• C-Reactive Protein, the Metabolic Syndrome, and Prediction of Cardiovascular Events in The Framingham Offspring Study— Martin K. Rutter, MD, Countess of Chester Hospital NHS Trust and Department of Medicine, University of Manchester, United Kingdom (Session #812-1, March 8, 11:00 a.m.)
• Fasting Glucose is an Independent Predictor of 30-Day Mortality in Nondiabetic Patients with Acute Myocardial Infarction: A Prospective Study—Mahmoud Suleiman, MD, Rambam Medical Center, Haifa, Israel (Session# 827-2, March 8, 4:15 p.m.)

Moderator: Prakash Deedwania, MD, VACCHA/UCSF School of Medicine, Fresno, CA
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

2:00 p.m.-2:45 p.m.
CHF—New tools strengthen heart failure management
Research sheds light on promising approaches to the diagnosis and management of patients with heart failure.

• The Effect of a Calcium Sensitizer or an Inotrope or None in Chronic Low Output Decompensated Heart Failure: Calcium Sensitizer or Inotrope or None in Low Output Heart Failure (CASINO) Study—Michael N. Zairis, MD, Department of Cardiology, Tzam's Hospital, Pirqeue, Greece
• False Positive Rates for Serum B-Type Natriuretic Peptide Testing in the Routine Clinical Setting—Nancy Sweitzer, University of Wisconsin, Madison, WI (Session #859-1, March 9, 4:00 p.m.)
• Pro B-Natriuretic Peptide (NT-proBNP) Measurement for the Emergency Diagnosis of Congestive Heart Failure: The ProBNP Investigation of Dyspnea in the Emergency Department (PRIDE) Study —James L. Januzzi, MD, Massachusetts General Hospital, Harvard Medical School, Boston, MA (Session #859-3, March 9, 4:30 p.m.)
• Impact of the AARB Candesartan in Preventing Diabetes in Patients with Heart Failure—Salim Yusuf, MD, McMaster University in Hamilton, Canada (Session #810-1, March 8, 11:00 a.m.)

Moderator: Barry Massie, MD, San Francisco Veterans Affairs Medical Center, University of California, San Francisco, CA
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

Press Conferences
WEDNESDAY, MARCH 10, 2004

8:00 a.m.-8:25 a.m.
Miscellaneous—Research round-up delivers good news and bad
Studies explore an array of topics critical to the care of patients with cardiovascular disease. One study adds weight to concerns about the cardiovascular risks linked to a popular arthritis drug, another delivers encouraging news about the effectiveness of drug-eluting stents in patients with diabetes, and a third suggests that performing CPR incorrectly can have devastating effects.

• Rofecoxib Increases Cardiovascular Events in Arthritis Patients but Celecoxib and Nonspecific Nonsteriodal Anti-Inflammatory Drugs Do Not: Results from a Large New England Health Care Claims Database—Andrew Whelton, MD, Universal Clinical Research Center, Inc., Hunt Valley, MD (Session #838-2, March 9, 10:45 a.m.)
• TAXUS IV Diabetic Subset Analysis: Improvements in 9-Month Outcomes in Diabetes on Oral Medication as well as Insulin—James B. Hermiller, St. Vincent Hospital, The Heart Center of Indiana, Indianapolis, IN (Session #1059-5, March 8, 12:00 p.m.)
• Excessive Ventilation During Cardiopulmonary Resuscitation Decreases Survival Rates in a Porcine Model of Cardiac Arrest—Demitris Yannopoulos, MD, University of Minnesota Medical Center, Minneapolis, MN (Session #1059-1, March 8, 12:00 p.m.)

Moderator: (TBD)
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)

8:30 a.m.-10:00 a.m.
Break for Session # 415: Late Breaking Clinical Trials III
A detailed look at the studies presented at the upcoming (10:30 a.m.) Press Conference on Late Breaking Clinical Trials

10:30 a.m.-11:15 a.m.
Late Breaking Clinical Trials III

• Cardiovascular Morbidity and Mortality in Patients with Diabetes in the EUROPA Study: Results from the PERSUADE Substudy—Kim M. Fox, MD, Royal Brompton Hospital, London, United Kingdom (Session #415, March 10, 8:30 a.m.)
• Ezetimibe Added to Statin Therapy Reduces LDL-C and Improves Goal Attainment in Patients With Hypercholesterolemia, Thomas A. Pearson, MD, Ph.D., University of Rochester School of Medicine and Dentistry, Rochester, NY (Session #415, March 10, 8:45 a.m.)
• The Effect of Intensive Lipid-Lowering, with or without Antioxidant Vitamins, vs. Moderate Lipid-Lowering on Ambulatory and Exercise-Induced Ischemia in Patients with Stable Coronary Disease: The Vascular Basis for the Treatment of Myocardial Ischemia Study—Peter H. Stone, MD, Brigham & Women's Hospital, Harvard Medical School, Boston, MA (Session #415, March 10, 9:06 a.m.)
• Guidelines Based Standardized Care Substantially Reduces Mortality in Medicare Patients with Acute Myocardial Infarction: The American College of Cardiology Guidelines Applied in Practice Program in Michigan—Kim A. Eagle, MD, University of Michigan Health System, Ann Arbor, MI (Session #415, March 10, 9:24 a.m.)
• Stress Myocardial Perfusion Scintigraphy for Tracking Prognosis and Monitoring the Success of Anti-Ischemic Therapies in Stable Survivors of Acute Myocardial Infarction: Results from the AdenosINe Sesamili Post InfaRction Evaluation (INSPIRE) Trial—John J. Mahmarian, MD, Section of Cardiology, Baylor College of Medicine, Methodist DeBakey Heart Center, The Methodist Hospital, Houston, TX (Session #415, March 10, 9:42 a.m.)

Moderator: (TBD)
  Listen to the news conference: HIGH BAND (DSL, cable, T1) or LOW BAND (dial-up)